Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.66 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.66 |
| ▸ | BCL2 | P10415 | 1/20 | 0.66 |
| ▸ | BID | P55957 | 1/20 | 0.66 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.66 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.66 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.66 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.66 |
| ▸ | BRAF | P15056 | 9/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239714 | 0.86 | BRAF (0.56) | BCL2A1MCL1BCL2BIDBCL2L1 | |
| SCHEMBL10058123 | 0.80 | MCL1 (0.66) | BCL2A1MCL1BCL2BIDBCL2L1 | |
| SCHEMBL2244145 | 0.79 | MCL1 (1.00) | BCL2A1MCL1BCL2BIDBCL2L1 | |
| SCHEMBL2242275 | 0.79 | BCL2A1 (0.64) | BCL2A1MCL1BCL2BIDBCL2L1 | |
| SCHEMBL29634065 | 0.79 | EP300 (0.65) | BCL2A1MCL1BCL2BCL2L1KEAP1 | |
| SCHEMBL28711122 | 0.79 | EP300 (0.65) | BCL2A1MCL1BCL2BCL2L1KEAP1 | |
| SCHEMBL2238806 | 0.78 | MCL1 (0.81) | BCL2A1MCL1BCL2BIDBCL2L1 | |
| SCHEMBL2240501 | 0.77 | BRAF (1.00) | BCL2A1MCL1BCL2BIDBCL2L1 | |
| SCHEMBL2245292 | 0.77 | BRAF (0.73) | BCL2A1MCL1BCL2BIDBCL2L1 | |
| SCHEMBL2242447 | 0.77 | BRAF (1.00) | BCL2A1MCL1BCL2BIDBCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142917-A1 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-06-07 | — | — | US | claimed |
| WO-2010102286-A2 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-09-10 | — | — | WO | claimed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-8466157-B2 | Proteasome inhibitors having chymotrypsin-like activity | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466157-B2 | Proteasome inhibitors having chymotrypsin-like activity | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466157-B2 | Proteasome inhibitors having chymotrypsin-like activity | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120142917-A1 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142917-A1 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142917-A1 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2010102286-A2 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010005534-A2 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010005534-A2 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | PSMB7, PSMD7, PSMB6 | BCL2A1 84/4885MCL1 62/4885BCL2 50/4885 |
| US-20120142917-A1 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | PSMB4, PSME4, PSMB1 | BCL2A1 1893/4885MCL1 751/4885BCL2 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.